Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials

R. Yerushalmi, B. Dong, J. W. Chapman, P. E. Goss, M. N. Pollak, M. J. Burnell, M. N. Levine, V. H.C. Bramwell, K. I. Pritchard, T. J. Whelan, J. N. Ingle, L. E. Shepherd, W. R. Parulekar, L. Han, K. Ding, K. A. Gelmon

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Methods: Data from chemotherapy trials MA.5 and MA.21; endocrine therapy MA.12, MA.14 and MA.27; and trastuzumab HERA/MA.24 were analyzed. The primary objective was to examine the effect of BMI change on breast cancer-free interval (BCFI) landmarked at 5 years; secondary objectives included BMI changes at 1 and 3 years; BMI changes on disease-specific survival (DSS) and overall survival (OS); and effects of baseline BMI. Stratified analyses included trial therapy and composite trial stratification factors.

Background: We hypothesized that increased baseline BMI and BMI change would negatively impact clinical outcomes with adjuvant breast cancer systemic therapy.

Results: In pre-/peri-/early post-menopausal chemotherapy trials (N = 2793), baseline BMI did not impact any endpoint and increased BMI from baseline did not significantly affect BCFI (P = 0.85) after 5 years although it was associated with worse BCFI (P = 0.03) and DSS (P = 0.07) after 1 year. BMI increase by 3 and 5 years was associated with better DSS (P = 0.01; 0.01) and OS (P = 0.003; 0.05). In pre-menopausal endocrine therapy trial MA.12 (N = 672), patients with higher baseline BMI had worse BCFI (P = 0.02) after 1 year, worse DSS (P = 0.05; 0.004) after 1 and 5 years and worse OS (P = 0.01) after 5 years. Increased BMI did not impact BCFI (P = 0.90) after 5 years, although it was associated with worse BCFI (P = 0.01) after 1 year. In post-menopausal endocrine therapy trials MA.14 and MA.27 (N = 8236), baseline BMI did not significantly impact outcome for any endpoint. BMI change did not impact BCFI or DSS after 1 or 3 years, although a mean increased BMI of 0.3 was associated with better OS (P = 0.02) after 1 year. With the administration of trastuzumab (N = 1395) baseline BMI and BMI change did not significantly impact outcomes.

Conclusions: Higher baseline BMI and BMI increases negatively affected outcomes only in pre-/peri-/early post-menopausal trial patients. Otherwise, BMI increases similar to those expected in healthy women either did not impact outcome or were associated with better outcomes.

Clinical Trials numbers: CAN-NCIC-MA5; National Cancer Institute (NCI)-V90-0027; MA.12-NCT00002542; MA.14-NCT00002864; MA.21-NCT00014222; HERA, NCT00045032;CAN-NCIC-MA24; MA-27-NCT00066573.

Original languageEnglish (US)
Pages (from-to)1560-1568
Number of pages9
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume28
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Breast Neoplasms
Weights and Measures
Survival
Therapeutics
Drug Therapy
National Cancer Institute (U.S.)
Clinical Trials

Keywords

  • BMI
  • disease specific survival
  • overall survival
  • triple negative
  • weight change

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Yerushalmi, R., Dong, B., Chapman, J. W., Goss, P. E., Pollak, M. N., Burnell, M. J., ... Gelmon, K. A. (2017). Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. Annals of oncology : official journal of the European Society for Medical Oncology, 28(7), 1560-1568. https://doi.org/10.1093/annonc/mdx152

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. / Yerushalmi, R.; Dong, B.; Chapman, J. W.; Goss, P. E.; Pollak, M. N.; Burnell, M. J.; Levine, M. N.; Bramwell, V. H.C.; Pritchard, K. I.; Whelan, T. J.; Ingle, J. N.; Shepherd, L. E.; Parulekar, W. R.; Han, L.; Ding, K.; Gelmon, K. A.

In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 28, No. 7, 01.07.2017, p. 1560-1568.

Research output: Contribution to journalArticle

Yerushalmi, R, Dong, B, Chapman, JW, Goss, PE, Pollak, MN, Burnell, MJ, Levine, MN, Bramwell, VHC, Pritchard, KI, Whelan, TJ, Ingle, JN, Shepherd, LE, Parulekar, WR, Han, L, Ding, K & Gelmon, KA 2017, 'Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 28, no. 7, pp. 1560-1568. https://doi.org/10.1093/annonc/mdx152
Yerushalmi, R. ; Dong, B. ; Chapman, J. W. ; Goss, P. E. ; Pollak, M. N. ; Burnell, M. J. ; Levine, M. N. ; Bramwell, V. H.C. ; Pritchard, K. I. ; Whelan, T. J. ; Ingle, J. N. ; Shepherd, L. E. ; Parulekar, W. R. ; Han, L. ; Ding, K. ; Gelmon, K. A. / Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2017 ; Vol. 28, No. 7. pp. 1560-1568.
@article{de6c2ed584ca4a7e84344d061914134c,
title = "Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials",
abstract = "Methods: Data from chemotherapy trials MA.5 and MA.21; endocrine therapy MA.12, MA.14 and MA.27; and trastuzumab HERA/MA.24 were analyzed. The primary objective was to examine the effect of BMI change on breast cancer-free interval (BCFI) landmarked at 5 years; secondary objectives included BMI changes at 1 and 3 years; BMI changes on disease-specific survival (DSS) and overall survival (OS); and effects of baseline BMI. Stratified analyses included trial therapy and composite trial stratification factors.Background: We hypothesized that increased baseline BMI and BMI change would negatively impact clinical outcomes with adjuvant breast cancer systemic therapy.Results: In pre-/peri-/early post-menopausal chemotherapy trials (N = 2793), baseline BMI did not impact any endpoint and increased BMI from baseline did not significantly affect BCFI (P = 0.85) after 5 years although it was associated with worse BCFI (P = 0.03) and DSS (P = 0.07) after 1 year. BMI increase by 3 and 5 years was associated with better DSS (P = 0.01; 0.01) and OS (P = 0.003; 0.05). In pre-menopausal endocrine therapy trial MA.12 (N = 672), patients with higher baseline BMI had worse BCFI (P = 0.02) after 1 year, worse DSS (P = 0.05; 0.004) after 1 and 5 years and worse OS (P = 0.01) after 5 years. Increased BMI did not impact BCFI (P = 0.90) after 5 years, although it was associated with worse BCFI (P = 0.01) after 1 year. In post-menopausal endocrine therapy trials MA.14 and MA.27 (N = 8236), baseline BMI did not significantly impact outcome for any endpoint. BMI change did not impact BCFI or DSS after 1 or 3 years, although a mean increased BMI of 0.3 was associated with better OS (P = 0.02) after 1 year. With the administration of trastuzumab (N = 1395) baseline BMI and BMI change did not significantly impact outcomes.Conclusions: Higher baseline BMI and BMI increases negatively affected outcomes only in pre-/peri-/early post-menopausal trial patients. Otherwise, BMI increases similar to those expected in healthy women either did not impact outcome or were associated with better outcomes.Clinical Trials numbers: CAN-NCIC-MA5; National Cancer Institute (NCI)-V90-0027; MA.12-NCT00002542; MA.14-NCT00002864; MA.21-NCT00014222; HERA, NCT00045032;CAN-NCIC-MA24; MA-27-NCT00066573.",
keywords = "BMI, disease specific survival, overall survival, triple negative, weight change",
author = "R. Yerushalmi and B. Dong and Chapman, {J. W.} and Goss, {P. E.} and Pollak, {M. N.} and Burnell, {M. J.} and Levine, {M. N.} and Bramwell, {V. H.C.} and Pritchard, {K. I.} and Whelan, {T. J.} and Ingle, {J. N.} and Shepherd, {L. E.} and Parulekar, {W. R.} and L. Han and K. Ding and Gelmon, {K. A.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1093/annonc/mdx152",
language = "English (US)",
volume = "28",
pages = "1560--1568",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials

AU - Yerushalmi, R.

AU - Dong, B.

AU - Chapman, J. W.

AU - Goss, P. E.

AU - Pollak, M. N.

AU - Burnell, M. J.

AU - Levine, M. N.

AU - Bramwell, V. H.C.

AU - Pritchard, K. I.

AU - Whelan, T. J.

AU - Ingle, J. N.

AU - Shepherd, L. E.

AU - Parulekar, W. R.

AU - Han, L.

AU - Ding, K.

AU - Gelmon, K. A.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Methods: Data from chemotherapy trials MA.5 and MA.21; endocrine therapy MA.12, MA.14 and MA.27; and trastuzumab HERA/MA.24 were analyzed. The primary objective was to examine the effect of BMI change on breast cancer-free interval (BCFI) landmarked at 5 years; secondary objectives included BMI changes at 1 and 3 years; BMI changes on disease-specific survival (DSS) and overall survival (OS); and effects of baseline BMI. Stratified analyses included trial therapy and composite trial stratification factors.Background: We hypothesized that increased baseline BMI and BMI change would negatively impact clinical outcomes with adjuvant breast cancer systemic therapy.Results: In pre-/peri-/early post-menopausal chemotherapy trials (N = 2793), baseline BMI did not impact any endpoint and increased BMI from baseline did not significantly affect BCFI (P = 0.85) after 5 years although it was associated with worse BCFI (P = 0.03) and DSS (P = 0.07) after 1 year. BMI increase by 3 and 5 years was associated with better DSS (P = 0.01; 0.01) and OS (P = 0.003; 0.05). In pre-menopausal endocrine therapy trial MA.12 (N = 672), patients with higher baseline BMI had worse BCFI (P = 0.02) after 1 year, worse DSS (P = 0.05; 0.004) after 1 and 5 years and worse OS (P = 0.01) after 5 years. Increased BMI did not impact BCFI (P = 0.90) after 5 years, although it was associated with worse BCFI (P = 0.01) after 1 year. In post-menopausal endocrine therapy trials MA.14 and MA.27 (N = 8236), baseline BMI did not significantly impact outcome for any endpoint. BMI change did not impact BCFI or DSS after 1 or 3 years, although a mean increased BMI of 0.3 was associated with better OS (P = 0.02) after 1 year. With the administration of trastuzumab (N = 1395) baseline BMI and BMI change did not significantly impact outcomes.Conclusions: Higher baseline BMI and BMI increases negatively affected outcomes only in pre-/peri-/early post-menopausal trial patients. Otherwise, BMI increases similar to those expected in healthy women either did not impact outcome or were associated with better outcomes.Clinical Trials numbers: CAN-NCIC-MA5; National Cancer Institute (NCI)-V90-0027; MA.12-NCT00002542; MA.14-NCT00002864; MA.21-NCT00014222; HERA, NCT00045032;CAN-NCIC-MA24; MA-27-NCT00066573.

AB - Methods: Data from chemotherapy trials MA.5 and MA.21; endocrine therapy MA.12, MA.14 and MA.27; and trastuzumab HERA/MA.24 were analyzed. The primary objective was to examine the effect of BMI change on breast cancer-free interval (BCFI) landmarked at 5 years; secondary objectives included BMI changes at 1 and 3 years; BMI changes on disease-specific survival (DSS) and overall survival (OS); and effects of baseline BMI. Stratified analyses included trial therapy and composite trial stratification factors.Background: We hypothesized that increased baseline BMI and BMI change would negatively impact clinical outcomes with adjuvant breast cancer systemic therapy.Results: In pre-/peri-/early post-menopausal chemotherapy trials (N = 2793), baseline BMI did not impact any endpoint and increased BMI from baseline did not significantly affect BCFI (P = 0.85) after 5 years although it was associated with worse BCFI (P = 0.03) and DSS (P = 0.07) after 1 year. BMI increase by 3 and 5 years was associated with better DSS (P = 0.01; 0.01) and OS (P = 0.003; 0.05). In pre-menopausal endocrine therapy trial MA.12 (N = 672), patients with higher baseline BMI had worse BCFI (P = 0.02) after 1 year, worse DSS (P = 0.05; 0.004) after 1 and 5 years and worse OS (P = 0.01) after 5 years. Increased BMI did not impact BCFI (P = 0.90) after 5 years, although it was associated with worse BCFI (P = 0.01) after 1 year. In post-menopausal endocrine therapy trials MA.14 and MA.27 (N = 8236), baseline BMI did not significantly impact outcome for any endpoint. BMI change did not impact BCFI or DSS after 1 or 3 years, although a mean increased BMI of 0.3 was associated with better OS (P = 0.02) after 1 year. With the administration of trastuzumab (N = 1395) baseline BMI and BMI change did not significantly impact outcomes.Conclusions: Higher baseline BMI and BMI increases negatively affected outcomes only in pre-/peri-/early post-menopausal trial patients. Otherwise, BMI increases similar to those expected in healthy women either did not impact outcome or were associated with better outcomes.Clinical Trials numbers: CAN-NCIC-MA5; National Cancer Institute (NCI)-V90-0027; MA.12-NCT00002542; MA.14-NCT00002864; MA.21-NCT00014222; HERA, NCT00045032;CAN-NCIC-MA24; MA-27-NCT00066573.

KW - BMI

KW - disease specific survival

KW - overall survival

KW - triple negative

KW - weight change

UR - http://www.scopus.com/inward/record.url?scp=85034591997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034591997&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx152

DO - 10.1093/annonc/mdx152

M3 - Article

C2 - 28379421

AN - SCOPUS:85034591997

VL - 28

SP - 1560

EP - 1568

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

ER -